Drug Trial Radar · NCT01341353
Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
Last checked: Nov 20, 2026Latest source record: Apr 25, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,800
Planned (sponsor's estimate)
Start
Apr 2011
Primary completion
Dec 2014
Study completion Dec 2015
Sponsor
- Lead sponsor
- Wuhan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Capital Medical University; Peking Union Medical College; Guangdong Provincial People's Hospital; Nanjing Medical University; West China Hospital; Dalian Medical University; Shanghai Chest Hospital
- First posted
- Apr 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.
Conditions
- Atrial Fibrillation
Interventions
catheter ablationProcedure
circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
Digaoxin,amiodarone,β receptor antagonist, Calcium AntagonistsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with all-cause deathTime frame: 3 month
- Number of participants with all-cause deathTime frame: 12 month
- Number of participants with all-cause deathTime frame: 24 month
- Number of participants with all-cause deathTime frame: 36 month
- severe blooding complicationsTime frame: 3 month
- severe blooding complicationsTime frame: 12 month
- severe blooding complicationsTime frame: 24 month
- severe blooding complicationsTime frame: 36 month
- cardio-cerebrovascular complicationsTime frame: 3 month
- cardio-cerebrovascular complicationsTime frame: 12 month
- cardio-cerebrovascular complicationsTime frame: 24 month
- cardio-cerebrovascular complicationsTime frame: 36 month
- Number of participants with cardiovascular death eventsTime frame: 3 month
- Number of participants with cardiovascular death eventsTime frame: 12 month
- Number of participants with cardiovascular death eventsTime frame: 24 month
- Number of participants with cardiovascular death eventsTime frame: 36 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renmin Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.